Eumentis Therapeutics Inc.

EuMentis Therapeutics Inc. is a privately held clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat neuropsychiatric conditions with high unmet need. The Company’s most advanced product candidate, EM-221, is a best-in-class oral PDE10A inhibitor designed to modulate the dopamine D2 pathway specifically in the striatum. EuMentis plans to initiate a phase 2 study of EM-221 for the treatment of Tourette Syndrome in H2 2023. EuMentis is also developing EM-113, an uncompetitive fast-off NMDA receptor antagonist for the treatment of Autism Spectrum Disorder patients with elevated brain glutamate levels as determined by MR spectroscopy. EuMentis is also expanding its pipeline through the development of extrasynaptic NMDAR antagonists for treatment of multiple conditions in which elevated glutamate levels contribute to the pathophysiology including Traumatic Brain Injury (TBI), at present funded by an award from the United States Department of Defense. EuMentis was founded in 2019 with the mission to develop novel therapies to improve the quality of life of patients suffering from central nervous system (“CNS”) disorders. Contact: Mark Tepper, Ph.D. President and CEO 617-413-3020 [email protected]

网站

www.eumentistx.com

Eumentis Therapeutics Inc.的外部链接

所属行业

制药业

规模

2-10 人

总部

Boston，MA

类型

私人持股

创立

2019

领域

Drug Development、Neuroscience、Autism和Tourette Syndrome